Skip to main content
Top
Published in: Virchows Archiv 4/2013

01-10-2013 | Case Report

Inhibin-expressing clear cell neuroendocrine tumor of the ampulla: an unusual presentation of von Hippel–Lindau disease

Authors: Hasan Gucer, Eva Szentgyorgyi, Shereen Ezzat, Sylvia L. Asa, Ozgur Mete

Published in: Virchows Archiv | Issue 4/2013

Login to get access

Abstract

von Hippel–Lindau (VHL) disease is a hereditary autosomal dominant disorder associated with deletions or mutations in the VHL tumor suppressor gene. Characteristically, up to 60 % of neuroendocrine tumors (NETs) associated with VHL disease display a spectrum of clear cell morphology including multivacuolated lipid-rich cell change. Unlike neurofibromatosis type 1 and multiple endocrine neoplasia type 1 syndromes, ampullary NETs have not been described in association with VHL disease. In this report, we discuss the features of an incidental ampullary clear cell NET occurring in a patient with pancreatic VHL disease including multiple pancreatic NETs. The ampullary lesion consisted of epithelial cells resembling lipoblasts or signet ring cells. In our case, all NETs showing clear cell change were positive for inhibin. While the underlying mechanism of this finding is largely unknown, it is of note that positivity for inhibin has not been observed in clear cell NETs associated with multiple endocrine neoplasia type 1 syndrome. Our case proves that NETs can develop in the ampullary region in patients with VHL; clear cell change can occur in these lesions and can mimic signet ring cell carcinoma. This issue is of clinical significance especially in small biopsy samples; thus, positivity for keratin alone should not be taken as evidence of an adenocarcinoma. Moreover, demonstration of inhibin expression in a NET with clear cell change along with other clinical stigmata should alert the diagnostician to the possibility of VHL disease. However, further larger series examining inhibin expression in both syndrome-related and sporadic clear cell NETs are needed to confirm our findings.
Literature
1.
3.
4.
go back to reference Bosman FT, Carneiro F, Hruban RH, Theise ND (eds) (2010) WHO classification of tumors of the digestive system. IARC, Lyon Bosman FT, Carneiro F, Hruban RH, Theise ND (eds) (2010) WHO classification of tumors of the digestive system. IARC, Lyon
5.
go back to reference Albores-Saavedra J, Hart A, Chablé-Montero F, Henson DE (2010) Carcinoids and high-grade neuroendocrine carcinomas of the ampulla of Cater: a comparative analysis of 139 cases from the surveillance, epidemiology, and end results program-a population based study. Arch Pathol Lab Med 134:1692–1696PubMed Albores-Saavedra J, Hart A, Chablé-Montero F, Henson DE (2010) Carcinoids and high-grade neuroendocrine carcinomas of the ampulla of Cater: a comparative analysis of 139 cases from the surveillance, epidemiology, and end results program-a population based study. Arch Pathol Lab Med 134:1692–1696PubMed
6.
go back to reference Sinkre PA, Murakata L, Rabin L, Hoang MP, Albores-Saavedra J (2001) Clear cell carcinoid tumor of the gallbladder: another distinctive manifestation of von Hippel-Lindau disease. Am J Surg Pathol 25:1334–1339PubMedCrossRef Sinkre PA, Murakata L, Rabin L, Hoang MP, Albores-Saavedra J (2001) Clear cell carcinoid tumor of the gallbladder: another distinctive manifestation of von Hippel-Lindau disease. Am J Surg Pathol 25:1334–1339PubMedCrossRef
7.
go back to reference Nafidi O, Nguyen BN, Roy A (2008) Carcinoid tumor of the common bile duct: a rare complication of von Hippel-Lindau syndrome. World J Gastroenterol 14:1299–1301PubMedCrossRef Nafidi O, Nguyen BN, Roy A (2008) Carcinoid tumor of the common bile duct: a rare complication of von Hippel-Lindau syndrome. World J Gastroenterol 14:1299–1301PubMedCrossRef
8.
go back to reference Chetty R, Kennedy M, Ezzat S, Asa SL (2004) Pancreatic endocrine pathology in von Hippel-Lindau disease: an expanding spectrum of lesions. Endocr Pathol 15:141–148PubMedCrossRef Chetty R, Kennedy M, Ezzat S, Asa SL (2004) Pancreatic endocrine pathology in von Hippel-Lindau disease: an expanding spectrum of lesions. Endocr Pathol 15:141–148PubMedCrossRef
9.
go back to reference Basturk O, Coban I, Adsay NV (2009) Pancreatic cysts: pathologic classification, differential diagnosis, and clinical implications. Arch Pathol Lab Med 133:423–438PubMed Basturk O, Coban I, Adsay NV (2009) Pancreatic cysts: pathologic classification, differential diagnosis, and clinical implications. Arch Pathol Lab Med 133:423–438PubMed
10.
go back to reference Chetty R, Ezzat S, Asa SL (2006) Microadenomatosis of the pancreas in von Hippel-Lindau disease. Am J Surg Pathol 30:1630PubMedCrossRef Chetty R, Ezzat S, Asa SL (2006) Microadenomatosis of the pancreas in von Hippel-Lindau disease. Am J Surg Pathol 30:1630PubMedCrossRef
11.
go back to reference Ramsay JA, Asa SL, van Nostrand AW, Hassaram ST, de Harven EP (1987) Lipid degeneration in pheochromocytomas mimicking adrenal cortical tumors. Am J Surg Pathol 11(6):480–486PubMedCrossRef Ramsay JA, Asa SL, van Nostrand AW, Hassaram ST, de Harven EP (1987) Lipid degeneration in pheochromocytomas mimicking adrenal cortical tumors. Am J Surg Pathol 11(6):480–486PubMedCrossRef
12.
go back to reference Thirabanjasak D, Basturk O, Altinel D, Cheng JD, Adsay NV (2009) Is serous cystadenoma of the pancreas a model of clear-cell-associated angiogenesis and tumorigenesis? Pancreatology 9(1–2):182–188PubMedCrossRef Thirabanjasak D, Basturk O, Altinel D, Cheng JD, Adsay NV (2009) Is serous cystadenoma of the pancreas a model of clear-cell-associated angiogenesis and tumorigenesis? Pancreatology 9(1–2):182–188PubMedCrossRef
13.
go back to reference Mylonis I, Sembongi H, Befani C, Liakos P, Siniossoglou S, Simos G (2012) Hypoxia causes triglyceride accumulation by HIF-1-mediated stimulation of lipin 1 expression. J Cell Sci 125(Pt 14):3485–3493PubMedCrossRef Mylonis I, Sembongi H, Befani C, Liakos P, Siniossoglou S, Simos G (2012) Hypoxia causes triglyceride accumulation by HIF-1-mediated stimulation of lipin 1 expression. J Cell Sci 125(Pt 14):3485–3493PubMedCrossRef
14.
go back to reference Shen GM, Zhao YZ, Chen MT, Zhang FL, Liu XL, Wang Y, Liu CZ, Yu J, Zhang JW (2012) Hypoxia-inducible factor-1 (HIF-1) promotes LDL and VLDL uptake through inducing VLDLR under hypoxia. Biochem J 441(2):675–683PubMedCrossRef Shen GM, Zhao YZ, Chen MT, Zhang FL, Liu XL, Wang Y, Liu CZ, Yu J, Zhang JW (2012) Hypoxia-inducible factor-1 (HIF-1) promotes LDL and VLDL uptake through inducing VLDLR under hypoxia. Biochem J 441(2):675–683PubMedCrossRef
15.
go back to reference Pelletier J, Bellot G, Gounon P, Lacas-Gervais S, Pouysségur J, Mazure NM (2012) Glycogen synthesis is induced in hypoxia by the hypoxia-inducible factor and promotes cancer cell survival. Front Oncol 2:18PubMedCrossRef Pelletier J, Bellot G, Gounon P, Lacas-Gervais S, Pouysségur J, Mazure NM (2012) Glycogen synthesis is induced in hypoxia by the hypoxia-inducible factor and promotes cancer cell survival. Front Oncol 2:18PubMedCrossRef
16.
go back to reference Fryer E, Serra S, Chetty R (2012) Lipid-rich (“clear cell”) neuroendocrine tumors of the pancreas in MEN I patients. Endocr Pathol 23(4):243–246PubMedCrossRef Fryer E, Serra S, Chetty R (2012) Lipid-rich (“clear cell”) neuroendocrine tumors of the pancreas in MEN I patients. Endocr Pathol 23(4):243–246PubMedCrossRef
17.
go back to reference Todoroki T, Sano T, Yamada S, Hirahara N, Toda N, Tsukada K, Motojima R, Motojima T (2007) Clear cell carcinoid tumor of the distal common bile duct. World J Surg Oncol 5:6.18 Todoroki T, Sano T, Yamada S, Hirahara N, Toda N, Tsukada K, Motojima R, Motojima T (2007) Clear cell carcinoid tumor of the distal common bile duct. World J Surg Oncol 5:6.18
18.
go back to reference Konishi E, Nakashima Y, Smyrk TC, Masuda S (2003) Clear cell carcinoid tumor of the gallbladder: a case without von Hippel-Lindau disease. Arch Pathol Lab Med 127:745–747PubMed Konishi E, Nakashima Y, Smyrk TC, Masuda S (2003) Clear cell carcinoid tumor of the gallbladder: a case without von Hippel-Lindau disease. Arch Pathol Lab Med 127:745–747PubMed
19.
go back to reference Ishida M, Shiomi H, Naka S, Tani T, Okabe H (2012) Clear cell neuroendocrine tumor G1 of the gallbladder without von Hippel-Lindau disease. Oncol Lett 4:1174–1176PubMed Ishida M, Shiomi H, Naka S, Tani T, Okabe H (2012) Clear cell neuroendocrine tumor G1 of the gallbladder without von Hippel-Lindau disease. Oncol Lett 4:1174–1176PubMed
20.
go back to reference Chetty R, Serra S (2010) Lipid-rich and clear cell neuroendocrine tumors (“carcinoids”) of the appendix: potential confusion with Goblet cell carcinoid. Am J Surg Pathol 34:401–404PubMedCrossRef Chetty R, Serra S (2010) Lipid-rich and clear cell neuroendocrine tumors (“carcinoids”) of the appendix: potential confusion with Goblet cell carcinoid. Am J Surg Pathol 34:401–404PubMedCrossRef
21.
go back to reference Singh R, Basturk O, Klimstra DS, Zamboni G, Chetty R, Hussain S, La Rosa S, Yilmaz A, Capelli P, Capella C, Cheng JD, Adsay NV (2006) Lipid-rich variant of pancreatic endocrine neoplasms. Am J Surg Pathol 30(2):194–200PubMedCrossRef Singh R, Basturk O, Klimstra DS, Zamboni G, Chetty R, Hussain S, La Rosa S, Yilmaz A, Capelli P, Capella C, Cheng JD, Adsay NV (2006) Lipid-rich variant of pancreatic endocrine neoplasms. Am J Surg Pathol 30(2):194–200PubMedCrossRef
22.
go back to reference Alam H, Maizels ET, Park Y, Ghaey S, Feiger ZJ, Chandel NS, Hunzicker-Dunn M (2004) Follicle-stimulating hormone activation of hypoxia-inducible factor-1 by the phosphatidylinositol 3-kinase/AKT/Ras homolog enriched in brain (Rheb)/mammalian target of rapamycin (mTOR) pathway is necessary for induction of select protein markers of follicular differentiation. J Biol Chem 279(19):19431–19440PubMedCrossRef Alam H, Maizels ET, Park Y, Ghaey S, Feiger ZJ, Chandel NS, Hunzicker-Dunn M (2004) Follicle-stimulating hormone activation of hypoxia-inducible factor-1 by the phosphatidylinositol 3-kinase/AKT/Ras homolog enriched in brain (Rheb)/mammalian target of rapamycin (mTOR) pathway is necessary for induction of select protein markers of follicular differentiation. J Biol Chem 279(19):19431–19440PubMedCrossRef
23.
go back to reference Young JM, McNeilly AS (2012) Inhibin removes the inhibitory effects of activin on steroid enzyme expression and androgen production by normal ovarian thecal cells. J Mol Endocrinol 48(1):49–60PubMedCrossRef Young JM, McNeilly AS (2012) Inhibin removes the inhibitory effects of activin on steroid enzyme expression and androgen production by normal ovarian thecal cells. J Mol Endocrinol 48(1):49–60PubMedCrossRef
24.
go back to reference Hirai S, Yamanaka M, Kawachi H, Matsui T, Yano H (2005) Activin A inhibits differentiation of 3T3-L1 preadipocyte. Mol Cell Endocrinol 232(1–2):21–26PubMedCrossRef Hirai S, Yamanaka M, Kawachi H, Matsui T, Yano H (2005) Activin A inhibits differentiation of 3T3-L1 preadipocyte. Mol Cell Endocrinol 232(1–2):21–26PubMedCrossRef
Metadata
Title
Inhibin-expressing clear cell neuroendocrine tumor of the ampulla: an unusual presentation of von Hippel–Lindau disease
Authors
Hasan Gucer
Eva Szentgyorgyi
Shereen Ezzat
Sylvia L. Asa
Ozgur Mete
Publication date
01-10-2013
Publisher
Springer Berlin Heidelberg
Published in
Virchows Archiv / Issue 4/2013
Print ISSN: 0945-6317
Electronic ISSN: 1432-2307
DOI
https://doi.org/10.1007/s00428-013-1465-6

Other articles of this Issue 4/2013

Virchows Archiv 4/2013 Go to the issue